Another clinical trial (phase I) carried out by WUSOM investigated the rise in cytotoxic effects of azacitidine when combined with CX-01, the inhibitor of HMGB1-RAGE/TLR4 interactions and chemokine receptor CXCR4 axis, on MDS and AML [128]. The gene discussed is CXCR4; the disease is myelodysplastic syndrome.